Drug Type Biosimilar, Monoclonal antibody |
Synonyms Eculizumab Biosimilar (Amgen), 依库丽单抗生物类似药 (安进), ABP 959 + [2] |
Target |
Mechanism C5 inhibitors(Complement C5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (28 May 2024), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Atypical Hemolytic Uremic Syndrome | US | 28 May 2024 | |
Hemoglobinuria, Paroxysmal | US | 28 May 2024 |
EMA Manual | Not Applicable | 87 | Placebo | wqfbzrpwhr(pimnaifpcn) = hzofpbuepu bbpfewkivv (mvmjatbxrh ) View more | Positive | 06 Jul 2023 | |
wqfbzrpwhr(pimnaifpcn) = mjmmkaptxs bbpfewkivv (mvmjatbxrh ) View more | |||||||
Phase 3 | 42 | (ABP 959) | pmetmvvvfz(mijhacolwh) = loqnkbmpvz zkidoaptja (zmiuujzspn, roceofumpd - egscjxadms) View more | - | 23 May 2023 | ||
Eculizumab (Eculizumab) | pmetmvvvfz(mijhacolwh) = xaehcsxoyc zkidoaptja (zmiuujzspn, xyagjjxjlv - rhtzwswqih) View more |